R

Read Gene SA
WSE:RDG

Watchlist Manager
Read Gene SA
WSE:RDG
Watchlist
Price: 4.95 PLN -0.2% Market Closed
Market Cap: 58.4m PLN
Have any thoughts about
Read Gene SA?
Write Note

Read Gene SA
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Read Gene SA
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
R
Read Gene SA
WSE:RDG
Total Liabilities & Equity
zł11.3m
CAGR 3-Years
-11%
CAGR 5-Years
-6%
CAGR 10-Years
0%
M
Mabion SA
WSE:MAB
Total Liabilities & Equity
zł179.3m
CAGR 3-Years
-2%
CAGR 5-Years
11%
CAGR 10-Years
2%
G
Genomed SA
WSE:GEN
Total Liabilities & Equity
zł12.1m
CAGR 3-Years
7%
CAGR 5-Years
5%
CAGR 10-Years
N/A
B
Bioton SA
WSE:BIO
Total Liabilities & Equity
zł790.4m
CAGR 3-Years
-3%
CAGR 5-Years
-3%
CAGR 10-Years
-9%
U
Urteste SA
WSE:URT
Total Liabilities & Equity
zł29.6m
CAGR 3-Years
250%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Synthaverse SA
WSE:SVE
Total Liabilities & Equity
zł293.2m
CAGR 3-Years
38%
CAGR 5-Years
27%
CAGR 10-Years
10%
No Stocks Found

Read Gene SA
Glance View

Market Cap
58.4m PLN
Industry
Biotechnology

Read-Gene SA engages in the medical research and testing. The company is headquartered in Szczecin, Woj. Zachodniopomorskie. The company went IPO on 2009-02-12. The company is focused on technologies which aim is to detect, prevent and treat malignant tumors. The firm specializes in three fields: chemoprevention, clinical trials and genetic testing. The company offers breast cancer, colon cancer and prostate cancer tests, as well as, medical consultancy, DNA tests and supplements. The firm operates one wholly owned subsidiary, Dieta Antyrakowa Read-Gene Sp. z o.o. Its major shareholder is GEN-PAT-MED Sp. z o.o.

RDG Intrinsic Value
2.52 PLN
Overvaluation 49%
Intrinsic Value
Price
R

See Also

What is Read Gene SA's Total Liabilities & Equity?
Total Liabilities & Equity
11.3m PLN

Based on the financial report for Jun 30, 2024, Read Gene SA's Total Liabilities & Equity amounts to 11.3m PLN.

What is Read Gene SA's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
0%

Over the last year, the Total Liabilities & Equity growth was -20%. The average annual Total Liabilities & Equity growth rates for Read Gene SA have been -11% over the past three years , -6% over the past five years .

Back to Top